Skip to main content
. 2022 Jun 7;12:911294. doi: 10.3389/fonc.2022.911294

Table 2.

Clinicopathological data and ALK results for all ALK IHC-positive (1+ to 3+) cases.

No. Tumor Type IHC score FISH NGS TNM/Stage****
1 * LCNEC 3 Positive EML4-ALK cT1 cN3 cM1c, IVB
2 ** LCNEC 3 NA EML4-ALK cT2 cN1 pM1c, IVB
3 *** LCNEC 3 Positive EML4-ALK cT3 cN3 cM1a, IVA
4 AC 3 Positive STRN-ALK pT2 pN2 cM0, IIIA
5 LCNEC 2 Positive NA pT1 pN3, cM0, IIIB
6 AC 1 Positive NA pT2 pN2, cM0, IIIA
7 LCNEC 3 Negative No fusion -
8 SCLC 3 Negative No fusion -
9 SCLC 3 NA No fusion -
10 SCLC 3 NA NA
11 SCLC 3 Negative NA -
12 AC 3 Negative No fusion -
13 AC 3 Negative No fusion -
14 AC 3 Negative NA -
15 AC 3 NA NA -
16 TC 3 NA NA -
17 TC 3 Negative No fusion -
18 SCLC 2 Negative No fusion -
19 AC 2 Negative No fusion -
20 AC 2 Negative No fusion -
21 TC 2 Negative No fusion -
22 TC 2 Negative No fusion -
23 TC 2 Negative NA -
24 LCNEC 1 Negative NA -
25 SCLC 1 NA NA -
26 SCLC 1 NA NA -
27 SCLC 1 Negative NA -
28 SCLC 1 Negative AN -
29 AC 1 Negative NA -
30 AC 1 NA NA -
31 AC 1 Negative NA -
32 AC 1 Negative NA -
33 AC 1 Negative NA
34 TC 1 Negative NA
35 TC 1 Negative NA
36 TC 1 Negative NA
37 TC 1 Negative NA
38 TC 1 Negative NA

AC, atypical carcinoid; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; LCNEC, large cell neuroendocrine carcinoma; NA, not available; NGS, next-generation sequencing; SCLC, small cell lung cancer; TC, typical carcinoid. *case report 1, **case report 2, ***case report 3, ****TNM stage at diagnosis.

Bold cases: ALK rearrangement positive by FISH or NGS.